Generate Biomedicines Stock Price, News & Analysis
Company Description
Generate Biomedicines (NASDAQ: GENB) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $1.8B, ranking #2,280 among all listed U.S. companies by market cap.
GENB stock has gained 8.7% over the past year. Shares last traded at $13.75.
This page provides a comprehensive overview of GENB stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Generate Biomedicines (GENB) stock last traded at $13.75. Over the past 12 months, the stock has gained 8.7%. At a market capitalization of $1.8B, GENB is classified as a small-cap stock with approximately 127.5M shares outstanding.
Latest News
Generate Biomedicines has 1 recent news article. Key topics include IPO, offering. View all GENB news →
SEC Filings
Generate Biomedicines has filed 5 recent SEC filings, including 4 Form 4, 1 Form 3. The most recent filing was submitted on March 12, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all GENB SEC filings →
Insider Radar
Insider buying activity at Generate Biomedicines over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
GENB Company Profile & Sector Positioning
Generate Biomedicines (GENB) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.